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Abstract: No abstract required
Response to Reviewers: Reviewer #1: The letter to the editor "Is the hypothalamic-pituitary-adrenal axis
disrupted in type 2 diabetes mellitus and is this relevant for bone health?" is well
written and makes an important contribution to the literature on the future directions
investigating the role of hypothalamic-pituitary-adrenal axis and type 2 diabetes with
bone metabolism and fracture risk.
We thank the reviewer for the appreciation.
Reviewer #2: General comment:
The authors commented about several papers published in Endocrine and further
discussed the relevance of the disruption of the HPA axis in DM2 patients for the
metabolic control and in addition to the bone function and health. They mention several
studies related to different factors that modulate glucocorticoid activity at bone tissue
including the new 11HSD1 inhibitors as potential candidates to ameliorate glucose
metabolism and additionally to improve osteoblast biology.
This is an interesting point and brief discussion.
Specific comments:
Q: It is suggested to include a brief paragraph mentioning the action mechanisms by
which glucocorticoids might damage the bone, in order to get in context the whole
discussion. Please, pay some attention to dissect those direct effects of glucocorticoids
in the bone to those due to the diabetic metabolic alterations or its complications in
other organs (nephropathy, micro/macro-angiopathy, neuropathy,…).
A: We agree with the referee. Accordingly, a paragraph summarizing the
glucocorticoids effect on bone has been added (page 2, lines 31-49). In addition, the
presence of cortical porosity in T2D related osteoporosis has been discussed (page 2,
lines 53-58)
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Q: Commenting a bit further in deep how the glucocorticoid receptor polymorphisms
might affect glycemic control and bone function would be of interest.
A: We agree. A paragraph briefly summarizing the possible role of glucocorticoid
receptor polymorphisms has been added (page 3, lines 7-22)
Q: Lines 40-44. "Thirdly, recent data showed that, as compared with subjects without
T2D, even in T2D patients with good metabolic control the cortisol secretion is
enhanced (although still normal as evaluated by the commonly used parameters of
cortisol secretion)…" Did the authors mean that T2D patients have cortisol levels in the
upper limit of the normal range? Or that common methodology is not adequate to
measure cortisol levels in T2D patients? Please, clarify and write it accordingly.
A: We meant that T2D patients have cortisol levels in the upper limit of the normal
range. This is now stated on page 3 (line 2).
Q: Line 47. "…the degree of cortisol secretion…". "degree" might be suppressed.
Several times repeated along the text.
A: We agree. The requested change has been made.
Q: Line 51. Correct "glycometbolic".
A: We apologize for the typos. The error has been corrected (page 3, line 9)
Q: Line 58. What "hormonal parameters" are the authors referring?
A: We meant that the basal cortisol homeostasis and androgens levels were not
affected by the 11-βhydroxysteroid dehydrogenase type 1 inhibitor. This is now
clarified in the new version of the manuscript (page 3, line 29)
Reviewer #3: Comments on letter to the editor (ENDO-D-1601061)
Q: The letter to the editor written by Eller-Vainicher and colleagues is dealing with an
intriguing topic, which is the HPA-axis alterations in type-2 diabetes and their potential
implications for osteoporosis and fractures. The letter is clear and well-written. I have
only a general comment. In the view of the authors, it seems that osteoporosis in
diabetes may be a consequence of HPA-axis disruption. Despite some evidence
provide support to the occurrence of alterations of indices of HPA-axis activity in
poorly-controlled diabetes, it is still debatable whether or not those alterations may
have clinical relevance. It should be considered that osteoporosis is a multifactorial
disease and, because of this, the potential causative effects of alteration of cortisol
secretion on osteoporosis and fracture risk is difficult to be understood.  Considering
that there are still no solid proofs regarding the etiology of hypercortisolism in type-2
diabetes, the suggestion of using 11beta-HSD inhibitors as an additional therapy for
osteoporosis is largely empirical. Even if disruption of cortisol secretion may have a
role in determining osteoporosis in type-2 diabetes, we still do not know whether
lowering cortisol secretion rate is more beneficial than a strict metabolic control of
diabetes.
A: We completely agree and thank the reviewer for this comment. The point raised has
been discussed in the new version of the manuscript (page 3, lines 40-54)
ASSOCIATE EDITOR:
Q: Please check Instructions for Authors related to "Letter to the Editor": Text is limited
to 750 words, with no abstract. There may be 1 figure, up to 3 references, ...
A: The manuscript now satisfies the Instructions for Authors related to "Letter to the
Editor”
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We read with interest the Editorial (1) and the two studies recently published on this Journal (2, 3) 
regarding the hypothalamic-pituitary-adrenal axis disruption in type 2 diabetes mellitus (T2D) and its 
consequences on the glycometabolic control.  
We agree with Raff and Magill that it would be prudent to screen  for a condition of subtle 
hypercortisolism all patients with poorly controlled T2D.  Beside this consideration, we would like to focus 
on the fact that, in addition to the metabolic control, the degree of cortisol secretion in T2D (even within the 
normal range) might be associated with the T2D related bone damage. Interestingly, there are interrelations 
and similarities between T2D and the condition of hypercortisolism not only regarding the pathogenesis of 
the glucose metabolism alteration in both conditions, but possibly also regarding the pathogenesis of the 
bone tissue alterations.  
Firstly, osteoporosis in T2D is characterized by a low bone turnover with a normal/decreased bone 
resorption and decreased bone apposition, partially due to the inhibition of the Wnt/β-catenin signaling. 
Indeed, this pathway is a critical regulator of osteoblastogenesis and in the T2D related osteoporosis its 
inhibition may lead to a preferential differentiation of the mesenchymal cells toward adipocytes than toward 
osteoblasts.  Similarly, in the glucocorticoid (GC) induced osteoporosis (GIO) the osteoblast differentiation 
is inhibited, due to a mesenchymal cells shift toward cells of the adipocytic lineage instead of toward 
osteoblasts. In addition, the GC excess decrease osteoblastic function and promote osteoblast and osteocyte 
apoptosis. This latter effect induces bone microarchitectural alterations, reducing bone quality. During the 
initial period of GC excess bone resorption is increased due to the enhanced levels of the receptor activator 
of nuclear factor kappa-B ligand and the decreased osteoprotegerin production in osteoblasts. As the GC 
exposure continues, bone remodeling decreases and the inhibition of bone apposition becomes the main 
pathogenetic mechanism of skeletal damage. Finally, the occurrence of an enhanced porosity of the cortical 
bone has been described as a further mechanism increasing the fracture risk in GIO.  
Secondly, in T2D patients, the diabetic chronic complications and the scarce glycometabolic control 
seem to be associated with the hip fracture risk. Indeed, the cortical porosity and the fracture risk are 
particularly increased in patients with T2D chronic complications. Interestingly, these latter patients have 




































































Thirdly, recent data show that, as compared with not diabetic subjects, in T2D patients (even in those 
with good metabolic control) the cortisol secretion is in the upper limit of the normal range, bone turnover is 
reduced and the vertebral fractures prevalence is associated with both cortisol secretion and the N363S 
sensitizing variant of the glucocorticoid receptor (GR) gene. Interestingly, the GR gene polymorphisms have 
been found to potentially influence both glycometabolic control and bone function. Indeed, the N363S 
polymorphism and the Bcl1 intronic mutation in the GR gene seem to increase GC sensitivity. These 
polymorphic variants (in heterozygosis for N363S and in homozygosis for Bcl1) seem to be associated with 
a worse metabolic profile and a decreased spinal and trochanteric bone density. However, an increased 
sensitivity of the GR should lower the circulating cortisol levels, so that their action at the GR should be 
correspondingly reduced. However, the GC sensitivity of bone may be increased in the conditions of 
endogenous or exogenous hypercortisolism. 
Finally, an agent inhibiting the 11-βhydroxysteroid dehydrogenase type 11 (11HSD1) activity, 
named INCB13739, has been found to ameliorate the glycometabolic control, without negatively affecting 
the basal cortisol homeostasis and androgens levels. Furthermore, animal and in vitro studies suggested the 
potential role of a 11HSD1  inhibitor in stimulating osteoblast differentiation.  
These considerations may be of clinical interest. Indeed, if osteoporosis in T2D was related, at least partially, 
to the degree cortisol secretion and/or sensitivity, the treatment with an 11HSD1 inhibitor could improve 
diabetic control and reduce the fracture risk at the same time.  
However, since the majority of the available studies are cross-sectional, it is still unclear if the 
alterations of the cortisol secretion may really influence the control of T2D. Furthermore, osteoporosis is a 
multifactorial disease and, therefore, the possible causative effects of the disrupted cortisol secretion on bone 
health is difficult to be understood. Finally, even if the altered cortisol secretion may contribute to the 
pathogenesis of the osteoporosis in T2D, it is to be determined whether lowering cortisol secretion rate is 
more beneficial for bone than a strict glycometabolic control. Therefore, the suggestion of using 11HSD 
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